CureVac Stock Jumps 16%

Shares of CureVac N.V. (CVAC) are gaining over 16% on Tuesday morning. The biopharmaceutical company announced that Dr. Alexander Zehnder will succeed Dr. Haas as new CEO on April 1, 2023.

CVAC is currently trading at $12.02, up $1.66 or 16.02%, on the Nasdaq. The stock opened its trading at $11.89 after closing previous day at $10.36. The stock has traded between $5.63 and $30.48 in the 52-week period.

Zehnder joins CureVac from Sanofi.

"The recent clinical validation of the power of CureVac's proprietary mRNA-technology platform represents an important inflection point to start turning the company into a relevant commercial player. We are therefore excited to welcome Alexander Zehnder at CureVac who brings extensive senior leadership experience from global companies such as Sanofi and Roche to the table. Over the course of his international career Alexander has significantly contributed to the commercial launch of practice-changing medicines. I am convinced that Alexander is ideally positioned to take CureVac to the next level as a relevant commercial player," said Jean Stéphenne, Chairman of the CureVac Supervisory Board.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT